Expected to begin pivotal phase III trial in March 2010 (2/10); FDA agrees on SPA for phase III (4/10)
Brand N/A Generic asimadoline
Company name Tioga Product type Non-speciality
Therapeutic category Gastrointestinal Key uses diarrhea predominant Irritable Bowel Syndrome (D-IBS)
Other Uses post-operative ileus Drug Class kappa opioid receptor agonist
Dosage From oral Expected Approval 2012+
FDA Filing N/A Last Update date April 07,2010
Link to news article
Link to clinicaltrials.gov
Link to press releases